WO2010104617A3 - Methods to induce a state of immune tolerance - Google Patents

Methods to induce a state of immune tolerance Download PDF

Info

Publication number
WO2010104617A3
WO2010104617A3 PCT/US2010/021994 US2010021994W WO2010104617A3 WO 2010104617 A3 WO2010104617 A3 WO 2010104617A3 US 2010021994 W US2010021994 W US 2010021994W WO 2010104617 A3 WO2010104617 A3 WO 2010104617A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune tolerance
induce
state
relates
methods
Prior art date
Application number
PCT/US2010/021994
Other languages
French (fr)
Other versions
WO2010104617A2 (en
Inventor
Salvatore Albani
Original Assignee
Salvatore Albani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvatore Albani filed Critical Salvatore Albani
Publication of WO2010104617A2 publication Critical patent/WO2010104617A2/en
Publication of WO2010104617A3 publication Critical patent/WO2010104617A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Abstract

This invention relates to novel methods to induce a state of immune tolerance in situations where it is desirable for clinical purposes. More specifically, this invention relates to novel methods to induce a state of immune tolerance in immune -mediated diseases. Even more specifically, this invention relates to inflammatory autoimmune disorders, including but not limited to rheumatoid arthritis, and other human autoimmune diseases and disorders, and the prevention and treatment of transplantation rejection and the effects of the method thereof comprising the induction of immune tolerance via a novel population of T cells with regulatory/ suppressive properties.
PCT/US2010/021994 2009-01-23 2010-01-25 Novel methods to induce a state of immune tolerance WO2010104617A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20583509P 2009-01-23 2009-01-23
US61/205,835 2009-01-23

Publications (2)

Publication Number Publication Date
WO2010104617A2 WO2010104617A2 (en) 2010-09-16
WO2010104617A3 true WO2010104617A3 (en) 2011-01-06

Family

ID=42026151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/021994 WO2010104617A2 (en) 2009-01-23 2010-01-25 Novel methods to induce a state of immune tolerance

Country Status (1)

Country Link
WO (1) WO2010104617A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439534A1 (en) * 2010-10-08 2012-04-11 TXCell Method for assessing the efficacy of a TR1 cell therapy in asubject
CN107073076A (en) * 2014-11-11 2017-08-18 株式会社日皮 Immune activation agent, cellular immunity activator and T cell multiplication agent
US11421000B2 (en) 2016-05-18 2022-08-23 Singapore Health Services Pte. Ltd. Pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
EP3956465A4 (en) * 2019-04-16 2023-04-05 Regents of the University of Minnesota Biomarker for transplantation tolerance induced by apoptotic donor leukocytes
CN110687281B (en) * 2019-08-26 2023-05-23 中国医学科学院肿瘤医院 Application of PD-L1 autoantibody in tumor prognosis evaluation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695459A (en) 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5612035A (en) 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6083919A (en) 1996-12-05 2000-07-04 University Of Florida Materials and methods for treating autoimmune disease
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
ES2539411T3 (en) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receiver for B7-4 and its use
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IZAWA ATSUSHI ET AL: "A novel alloantigen-specific CD8(+)PD1(+) regulatory T cell induced by ICOS-B7h blockade in vivo", JOURNAL OF IMMUNOLOGY, vol. 179, no. 2, July 2007 (2007-07-01), pages 786 - 796, XP009131394, ISSN: 0022-1767 *
SARESELLA MARINA ET AL: "CD4+CD25+FoxP3+PD1 - regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy", FASEB JOURNAL, vol. 22, no. 10, October 2008 (2008-10-01), pages 3500 - 3508, XP009131395, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
WO2010104617A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
WO2011094259A3 (en) Cd127 binding proteins
IL264498B (en) Novel compositions and methods for the treatment of immune related diseases
WO2007140472A3 (en) Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
JO3266B1 (en) Silent Fc variants of anti-CD40 antibodies
WO2010104617A3 (en) Methods to induce a state of immune tolerance
WO2011079308A3 (en) Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
WO2014011881A3 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
NZ590994A (en) Anti il-7r antibodies treatment of autoimmune and inflammatory disease
WO2008106134A3 (en) Engineered anti-il-23r antibodies
WO2012001647A3 (en) C10rf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2012083024A8 (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells
EP2652126A4 (en) Treatment of immune-related diseases and disorders using amnion derived adherent cells
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2007100643A3 (en) Methods of using antibodies against human il-22
MX2015007034A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof.
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
IN2012DN03362A (en)
WO2012087160A3 (en) Anti-inflammatory proteins and methods of preparation and use thereof
HK1201538A1 (en) Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis 14-3-3
WO2013056049A3 (en) Tubular prostheses
MX2013011421A (en) Pyrazolo pyrimidine derivatives.
EP2164500A4 (en) The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
MX361773B (en) Tlr3 binding agents.
WO2009155301A3 (en) Multipotent neural cells
WO2010013143A3 (en) Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10703726

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10703726

Country of ref document: EP

Kind code of ref document: A2